[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
In: The Lancet Oncology, Jg. 25 (2024-05-01), Heft 5, S. 563-571
academicJournal
Zugriff:
Titel: |
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
|
---|---|
Autor/in / Beteiligte Person: | Emmett, Louise ; Subramaniam, Shalini ; Crumbaker, Megan ; Nguyen, Andrew ; Joshua, Anthony M ; Weickhardt, Andrew ; Lee, Sze-Ting ; Ng, Siobhan ; Francis, Roslyn J ; Goh, Jeffrey C ; Pattison, David A ; Tan, Thean Hsiang ; Kirkwood, Ian D ; Gedye, Craig ; Rutherford, Natalie K ; Sandhu, Shahneen ; Kumar, Aravind Ravi ; Pook, David ; Ramdave, Shakher ; Nadebaum, David P ; Voskoboynik, Mark ; Redfern, Andrew D ; Macdonald, William ; Krieger, Laurence ; Schembri, Geoff ; Chua, Wei ; Lin, Peter ; Horvath, Lisa ; Bastick, Patricia ; Butler, Patrick ; Zhang, Alison Yan ; Yip, Sonia ; Thomas, Hayley ; Langford, Ailsa ; Hofman, Michael S ; McJannett, Margaret ; Martin, Andrew James ; Stockler, Martin R ; Davis, Ian D |
Zeitschrift: | The Lancet Oncology, Jg. 25 (2024-05-01), Heft 5, S. 563-571 |
Veröffentlichung: | 2024 |
Medientyp: | academicJournal |
ISSN: | 1470-2045 (electronic) |
DOI: | 10.1016/S1470-2045(24)00135-9 |
Sonstiges: |
|